Feedback

Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors

Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Weidemann, Sören;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Noori, Nessar Ahmad;
ORCID
0000-0002-1572-8200
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Lennartz, Maximilian;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Reiswich, Viktor;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Dum, David;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Menz, Anne;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Chirico, Viktoria;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Hube-Magg, Claudia;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Fraune, Christoph;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Bawahab, Ahmed Abdulwahab;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Bernreuther, Christian;
ORCID
0000-0003-0158-4258
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Simon, Ronald;
ORCID
0000-0002-4257-856X
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Clauditz, Till S.;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Sauter, Guido;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Hinsch, Andrea;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Kind, Simon;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Jacobsen, Frank;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Steurer, Stefan;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Minner, Sarah;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Burandt, Eike;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Marx, Andreas H.;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Krech, Till;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Lebok, Patrick;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Büscheck, Franziska;
Affiliation
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Höflmayer, Doris

As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2022 by the authors.

Use and reproduction: